CD274 and hepatocellular carcinoma: Therapies combining AA agents plus ICB have shown their efficiency in phase III clinical trials (84) and have been recently approved in different locations (i) atezolizumab (anti-PD-L1) and bevacizumab with chemotherapy in NSCLC (85) (ii) atezolizumab and bevacizumab in unresectable HCC (86) (iii) pembrolizumab (anti-PD-1) plus lenvatinib (TKI) in advanced endometrial cancer (87) (iv) pembrolizumab (anti-PD-1) plus axitinib in RCC (88) and v) axitinib plus avelumab (an anti-PD-L1) in RCC (89).